Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

71 questions · 71 findings · 3 reviews

No studies found 16 · 22.5%GRADE not reported 0 · 0%Very low 13 · 18.3%Low 21 · 29.6%Moderate 16 · 22.5%High 5 · 7%

Summary of findings: anti‐pseudomonal antibiotics vs placebo

Antibiotic resistance: frequency of tobramycin‐resistant P aeruginosa · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: anti‐pseudomonal antibiotics showed no clear difference in antibiotic resistance: frequency of tobramycin‐resistant P aeruginosa compared with placebo (moderate certainty).

1 finding from 1 review

Summary of findings: aztreonam lysine for inhalation vs tobramycin

Need for antibiotics see pulmonary exacerbations · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: aztreonam lysine for inhalation probably leads to lower pulmonary exacerbations: need for additional antibiotics compared with tobramycin (moderate certainty).

1 finding from 1 review

Summary of findings: aztreonam lysine for inhalation vs tobramycin

Adverse events: number of treatment‐related adverse events · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: aztreonam lysine for inhalation probably leads to higher adverse events: number of treatment‐related adverse events compared with tobramycin (moderate certainty).

1 finding from 1 review

Summary of findings: tobramycin for inhalation powder vs tobramycin

Exacerbations (number of people experiencing ≥ 1 exacerbations) · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

Summary of findings: tobramycin for inhalation powder showed no clear difference in pulmonary exacerbations: number of participants experiencing… compared with tobramycin (moderate certainty).

1 finding from 1 review